Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare DIMETHYL FUMARATE (Dimethyl Fumarate) and SIPONIMOD (MAYZENT) — clinical data, side effects, and patient experiences.
Dimethyl Fumarate, Tecfidera · Other
How it works
12.1 Mechanism of Action The mechanism by which dimethyl fumarate (DMF) exerts its therapeutic effect in multiple sclerosis is unknown. DMF and the metabolite, monomethyl fumarate ...
Approved for
MAYZENT, Mayzent · S1P Receptor Modulator
How it works
12.1 Mechanism of Action Siponimod is an S1P receptor modulator. Siponimod binds with high affinity to S1P receptors 1 and 5. Siponimod blocks the capacity of lymphocytes to egress...
Approved for
Estimated frequency (%) based on clinical trial data
No head-to-head clinical studies found for DIMETHYL FUMARATE vs SIPONIMOD.
DIMETHYL FUMARATE is a Other, while SIPONIMOD belongs to the S1P Receptor Modulator class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.
Both medications are approved for to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, to include clinically isolated syndrome. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
DIMETHYL FUMARATE carries 4 FDA warnings. SIPONIMOD carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.